As the diagnosis of prostate cancer in the PSA grey zone is of particular interest, the decision curve analysis focused on this group of patients, while the DCAs for the overall cohorts are reported in the supplemental data (Supplemental Figure 3 and Supplemental Tables 3, 4). This evidence concerns the gene KLK3 and Familial prostate cancer.